Leukapheresis market in Asia Pacific to hit USD 36 million by 2027, according to Gen Consulting Company

2022-06-18 08:05:47 UTC | Healthcare & Pharmaceuticals
Leukapheresis market in Asia Pacific to hit USD 36 million by 2027, according to Gen Consulting Company
Leukapheresis is a laboratory procedure in which white blood cells are separated from a sample of blood. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy. The leukapheresis market in Asia Pacific is likely to register a CAGR of over 8.3% with an incremental growth of USD 14 million during the forecast period 2021-2027.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into leukapheresis market in Asia Pacific. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the leukapheresis industry.

This industry report offers market estimates and forecasts of the Asia Pacific market, followed by a detailed analysis of the product, application, end user, and country. The Asia Pacific market for leukapheresis can be segmented by product: leukapheresis devices, leukapheresis disposables. In Asia Pacific, the leukapheresis disposables segment made up the largest share of the leukapheresis market. Leukapheresis market is further segmented by application: research, therapies. Based on end user, the leukapheresis market is segmented into: blood centers, hospitals & infusion centers, enterprises, academic & research institutes. On the basis of country, the leukapheresis market also can be divided into: Australia, China, India, Japan, South Korea, Rest of Asia Pacific.

By product:
- leukapheresis devices
- leukapheresis disposables

By application:
- research
- therapies

By end user:
- blood centers
- hospitals & infusion centers
- enterprises
- academic & research institutes

By country:
- Australia
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific

The report also provides a detailed analysis of several leading leukapheresis market vendors that include AllCells Corporation, Asahi Kasei Corporation, BioIVT LLC, Fresenius SE & Co. KGaA, Haemonetics Corporation, HemaCare Corporation (Charles River Laboratories International, Inc.), Macopharma, STEMCELL Technologies Inc., StemExpress, LLC, Terumo Corporation, among others.

Historical & Forecast Period
This research report provides analysis for each segment from 2017 to 2027 considering 2020 to be the base year.

Read Full Report : https://gen-cons.com/store/leukapheresis-market-in-asia-pacific

Scope of the Report
- To analyze and forecast the market size of the leukapheresis market in Asia Pacific.
- To classify and forecast the leukapheresis market in Asia Pacific based on product, application, end user, country.
- To identify drivers and challenges for the leukapheresis market in Asia Pacific.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the leukapheresis market in Asia Pacific.
- To identify and analyze the profile of leading players operating in the leukapheresis market in Asia Pacific.

Why Choose This Report
- Gain a reliable outlook of the leukapheresis market in Asia Pacific forecasts from 2021 to 2027 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.